The drugs, all three of which are anti-malarial, were bought for just over £4 million and will bring Alliance “into new territories and mark [their] first significant steps onto the continent” says Finance Director Richard Wright. Alliance may have to pay a further £1 million dependant on sales of the drugs.
Alliance have also added significant experience in the appointment of new country managers for France and central Europe. Chief Executive John Dawson has said “We are delighted to add these important anti-malarial brands to the Alliance portfolio,” before expressing his delight at the addition of experience to spearhead Alliance’s European expansion.
Looking for a job in the pharmaceutical sector? Start by looking here